Abstract
Background Recognizing new and improved diagnostics as a key step to reducing the global tuberculosis (TB) burden, the World Health Organization (WHO) publishes target product profiles (TPPs) to guide development of novel TB diagnostics; however, TPPs have not included the preferences of people undergoing TB testing. Understanding their preferences is crucial for optimizing the acceptability and uptake of TB diagnostic services.
Design/methods We conducted a discrete choice experiment (DCE) among adults with presumptive or microbiologically confirmed TB in 5 countries (Philippines, Vietnam, South Africa, Uganda, and India). The DCE evaluated preferences for 5 TB diagnostic test attributes (sample type, accuracy, cost, location, time to result) with 3-4 levels per attribute. We estimated mean preference weights for attribute levels using Hierarchical Bayesian models and conducted willingness-to-trade analyses for preferred test features.
Results Among 1,033 participants (median age 43 years, Interquartile Range: 30-55), 52% were female, 10% had HIV, 14% had diabetes, 36% had current or prior TB), the most strongly valued test features were free cost, high diagnostic accuracy, and rapid (within 15 minutes) result availability. Among less valued attributes, facility-based testing (location) and sputum (sample type) were most preferred. The relative importance of attributes and their levels differed by country. In willingness-to-trade simulations, participants in each country were willing to trade 10-20% lower accuracy for the availability of rapid tests but were unwilling to trade accuracy for alternative sample types (e.g., tongue-swab, urine, blood) or testing locations (e.g., home- or community-based); participants in India and Vietnam were willing to pay $3.20 and $4.00 USD, respectively, for tests with rapid results.
Conclusions Persons accessing TB services in five high-burden countries universally value free cost, high diagnostic accuracy, and rapid result availability. However, many were willing to accept lower test accuracy and some were willing to incur small out-of-pocket costs to access rapid tests. To align with preferences of TB-affected communities, future TPP updates and new test development should prioritize rapid results while maintaining high accuracy and minimizing costs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded under the NIH/NIAID award U01AI152087
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional approval was obtained from De La Salle Medical Health & Sciences Institute in the Philippines, Hanoi Lung Hospital in Vietnam, Stellenbosch University in South Africa, Makerere University in Uganda, Christian Medical College in India, University of Heidelberg in Germany, and the University of California San Francisco
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are included in the manuscript or available upon reasonable request to the authors
